Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Sep 20;8:441. doi: 10.1186/1743-422X-8-441

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright ©2011 Golden et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Efficacy of immune rabbit sera in a mouse model of progressive vaccinia. Groups of 6-week old SCID/NCr mice (n = 7/group) were scarified with VACV, then treated i.p. with PBS (placebo), VIGIV (10 mg), QVPA (1:10; 1:100), or NRS (1:10) on days 2, 5, 10, and 15. (A) Survival was monitored out to 60 days postinfection. VIGIV and both QVPA dose groups showed a statistically significant increase (p < 0.05) in median survival time compared to placebo or NRS. (B) Primary lesion size on day 19 was determined from digital photographs and compared using one way ANOVA and Tukey's multiple comparison. Treatment with VIGIV or either dose of QVPA resulted in statistically significant reduction (p < 0.01) in lesion area.